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Abstract 
Treatment of metastatic renal cell cancer (mRCC) currently focuses on inhibition of the 
vascular endothelial growth factor pathway and the mammalian target of rapamycin 
(mTOR) pathway. Obesity confers a higher risk of RCC. However, the inf luence of obesity 
on clinical outcomes in mRCC in the era of targeted therapy is less clear. This review 
focuses on the impact of body composition on targeted therapy outcomes in mRCC. The 
International Metastatic Renal Cell Carcinoma Database Consortium database has the 
largest series of patients evaluating the impact of body mass index (BMI) on outcomes in 
mRCC patients treated with targeted therapy. Overall survival was significantly 
improved in overweight patients (BMI ≥ 25 kg/m2), and this observation was externally 
validated in patients who participated in Pfizer trials. In contrast, sarcopenia is 
consistently associated with increased toxicity to inhibitors of angiogenesis and mTOR. 
Strengthening patients with mRCC and sarcopenia, through a structured exercise 
program and dietary intervention, may improve outcomes in mRCC treated with targeted 
therapies. At the same time, the paradox of obesity being a risk factor for RCC while 
offering a better overall survival in response to targeted therapy needs to be further 
evaluated. 
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Introduction
Treatment of metastatic renal cell cancer 
(mRCC) currently focuses on inhibition of 
the vascular endothelial growth factor 
(VEGF) pathway and the mammalian target 
of rapamycin (mTOR) pathway. Although 
predictive biomarkers for targeted therapy 
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Table 1. Comparison of multivariable prognostic factor models in metastatic renal cell 
carcinoma 
Model MSKCC IMDC criteria 
 Motzer et al. (2, 3) Heng et al. (1) 
Patient population 463 patients treated with 
interferon alpha on prospective 
clinical trials 
645 patients treated with 
sunitinib, sorafenib, or 
bevacizumab at multiple North 
American centers 
Prognostic factors KPS < 80% KPS < 80% 
LDH > 1.5 × ULN Corrected calcium > ULN 
Corrected calcium > 10 mg/dL  Hemoglobin < LLN 
(2.5 mmol/L) Disease-free interval < 1 year  
Hemoglobin < LLN Neutrophils > ULN 
Disease-free interval < 1 year Platelets > ULN 
Favorable risk No risk factors, mOS 30 months No risk factors, mOS not reached 
Intermediate risk 1 risk factor, mOS 14 months 1–2 risk factors, mOS 27 months 
Poor risk 2–3 risk factors, mOS 5 months 3 or more risk factors, mOS 8.8 
months 
IMDC: International Metastatic Renal Cell Carcinoma Database Consortium; KPS: Karnofsky 
performance status; LDH: Lactate dehydrogenase; LLN: Lower limit of normal; mOS: median 
overall survival; MSKCC: Memorial Sloan-Kettering Cancer Center; ULN: Upper limit of normal. 
have yet to be validated, there are 
prognostic models that can stratify mRCC 
patients into low-, intermediate-, and high-
risk groups. Two commonly used models 
include the International Metastatic Renal 
Cell Carcinoma Database Consortium 
(IMDC) model (1) and the Memorial Sloan-
Kettering Cancer Center (MSKCC) criteria 
(2, 3) (Table 1). 
Obesity confers a higher risk of RCC (4–
7); however, the influence of obesity on 
clinical outcomes in mRCC in the era of 
targeted therapy is less clear. The World 
Health Organization utilizes body mass 
index (BMI; weight divided by height 
squared) to define the terms “overweight” 
(BMI 25.0–29.9 kg/m2) and “obesity” 
(BMI ≥ 30 kg/m2) (8). However, BMI does 
not accurately reflect body composition, 
the proportion of lean tissue to fat; nor 
does BMI account for sarcopenia, the 
loss of skeletal muscle tissue. Computed 
tomography (CT) is often used to assess 
response to therapy as part of routine 
care. Cross-sectional imaging can be 
utilized to quantify skeletal muscle 
density (SMD) and adipose tissue. In 
addition, relative distribution of fat can 
be localized to the visceral or 
subcutaneous compartments (visceral 
fat area [VFA] and superficial fat area 
[SFA]). 
Higher BMI may negatively influence 
outcomes through commonly associated 
comorbidities of diabetes and cardiovascular 
disease (9). It may alter drug concentrations 
and pharmacokinetics of targeted therapies 
that are dosed independent of weight. 
Obesity may activate oncogenic pathways 
and create an inflammatory state. This is 
postulated to occur via elevations in 
interleukins (IL-6, IL-1β, and IL-1 receptor 
antagonist), tumor necrosis factor, and C-
reactive protein (10). Furthermore, a 
proangiogenic state is created by the 
production of factors such as VEGF and 
leptin by adipose tissue (11). An obese body 
composition also can promote and activate 
the mTOR pathway through reactive oxygen 
species (12), as well as elevated levels of 
insulin and insulin-like growth factor (13). 
Obesity is paradoxically associated with 
better prognosis, particularly in the 
setting of nephrectomized patients with 
RCC (14, 15). Table 2 summarizes the 
findings of studies, which examine this 
relationship between survival rates in 
mRCC and body composition metrics. This 
review paper will focus on the impact of 
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Table 2. Retrospective studies evaluating the impact of body composition on outcome in 
metastatic renal cell carcinoma patients treated with targeted therapies 
Study population Body composition 
cutpoint for 
obesity 
Impact on clinical outcomes 
Choueiri et al. 475 North 
American patients included in 
the IMDC database (16) 
BMI ≥ 30 kg/m2 High BMI associated with 
improved OS 
HR 0.67 
(95% CI 0.49–0.91, p = 0.01) 
Albiges et al. 1,975 patients (17) 
 
BMI ≥ 25 kg/m2 High BMI associated with 
improved median OS (25.6 vs 
17.1 months, p < 0.0001) 
Albiges et al. 4,657 patients 
from Pfizer trials (18) 
BMI ≥ 25 kg/m2 High BMI: improved OS (HR 
0.830, p = 0.0008, 95% CI 
0.743–0.925) 
BMI: body mass index; BSA: body surface area; HR: hazard ratio; OS: overall survival;  
CI: confidence interval. 
body composition on targeted therapy 
outcomes in mRCC. 
Literature search strategy 
A PubMed and Medline literature search 
was performed for the time period 1994 to 
2015 with the following search terms: 
sarcopen*, BMI, body mass, cachexia, 
BSA, body surface area, body 
composition, renal cell ca*, RCC, kidney 
cancer, prognos*, outcome*, response, 
predict*, mTOR, everolimus, sirolimus, 
sunitinib, PD1, PDL1. Additionally, 
American Society of Clinical Oncology 
meeting proceedings were searched with 
the following search terms: BMI, body, 
BSA, renal cell. Articles in any language 
were included, and all levels of evidence 
were considered. The retrieved articles’ 
relevant references were also reviewed 
for possible inclusion. Eleven articles 
(eight published, three abstracts) 
evaluated body composition as a 
prognostic factor for targeted therapy 
outcomes in mRCC. 
Impact of BMI on outcomes 
Body composition and its potential 
influence on targeted therapy outcomes 
were initially assessed in a retrospective 
study of 475 mRCC patients treated with 
antiangiogenic therapy. Choueiri et al. (16) 
identified that obesity (BMI > 30 kg/m2) 
was independently associated with greater 
overall survival (OS) (hazard ratio [HR] 
0.67, 95% confidence interval [CI] 0.49–
0.91, p = 0.01), after adjusting for the 
IMDC model criteria. The IMDC updated 
this analysis in a larger dataset of 1,975 
patients treated with targeted therapy (17). 
Overweight or obese patients (BMI ≥ 25 
kg/m2) had a significantly longer median 
OS compared with underweight or normal 
patients (25.6 vs 17.1 months, p < 0.0001), 
which remained significant after adjusting 
for IMDC model criteria. 
This finding was externally validated in a 
cohort of 4,657 mRCC patients on phase II 
and III Pfizer trials from 2003 to 2013 (18). 
Overweight or obese patients (BMI ≥ 25 
kg/m2) had a longer OS, in comparison 
with the low BMI group (BMI < 25 kg/m2) 
(23.4 vs 14.5 months, HR 0.830, 95% CI 
0.743–0.925, p = 0.0008), while controlling 
for the IMDC prognostic risk criteria. 
Similarly, high BMI was associated with 
improved progression-free survival (PFS) 
(HR 0.821, 95% CI 0.746–0.903, p < 
0.0001) and response rate (odds ratio 
1.527, 95% CI 1.258–1.855, p < 0.001), in 
contrast to low BMI. Interestingly, the 
results were similar when stratified by line 
of therapy. The favorable outcome 
associated with elevated BMI was observed 
only in clear cell mRCC, when stratified by 
histology. 
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There was question of whether tolerability of 
therapy in higher BMI patients played a role 
in producing these findings. However, in the 
IMDC dataset, rates of early discontinuation 
due to adverse events did not differ between 
the two BMI groups, and therefore this was 
unlikely a cause of bias (17). Additionally, 
the toxicity patterns were similar in the 
high- and low-BMI groups in the external 
Pfizer validation set (18). 
The biologic rationale for the association 
between BMI and outcomes is not clear. 
Fatty acid synthase (FASN) is a key enzyme 
involved in the production of fatty acids. 
FASN has emerged as a metabolic oncogene 
with an important role in tumor growth and 
survival (19). There was a trend to improved 
OS in the elevated BMI group (p = 0.07) in 
the Cancer Genome Atlas clear cell mRCC 
dataset (n = 61) (18). High BMI was 
associated with low FASN gene expression 
(p = 0.034), and FASN expression (using the 
median as a cutpoint) was inversely 
associated with OS (p = 0.002). FASN gene 
was evaluated using immunohistochemistry 
(IHC) in the IMDC biospecimen cohort (17). 
Median OS was significantly improved in 
FASN IHC negative compared with positive 
patients (27.5 vs 14.5 months, p = 0.005). 
FASN metabolism may contribute to the 
development of mRCC and therefore may 
represent a novel therapeutic target. These 
results are hypothesis-generating. 
Volumetric assessment of body 
composition 
BMI is a relatively crude measurement of 
body composition. Other groups have 
evaluated more granular metrics of body 
composition such as volumetric assessment 
of fat and muscle (Table 3). Software 
programs can be used to identify the 
visceral and subcutaneous visceral adipose 
compartments using Houndsfield units at 
specific landmarks on CT, followed by 
calculation of the cross-sectional area. In 
contrast to the IMDC data, BMI was not 
prognostic in other smaller retrospective 
studies that incorporate these volumetric 
assessments (20–22). Steffens et al. (20) 
evaluated the impact of baseline BMI, body 
surface area (BSA, m2), VFA, and SFA in 
116 mRCC patients. VFA and SFA were 
calculated with ImageJ software using the 
umbilicus as the landmark. The cutoffs 
used were a BMI ≥ 30 kg/m2, a BSA above 
the European average > 1.74 for women and 
BSA > 1.98 for men, and finally an SFA or a 
VFA above the median of the patient cohort. 
On multivariate Cox regression analysis 
incorporating histological subtype and 
MSKCC status, there was no significant 
association between PFS and OS with 
elevated BMI and BSA. Elevated SFA and 
VFA were independently associated with 
improved OS and PFS (SFA: HR 3.41, 95% 
CI 1.61–7.25, p = 0.001; VFA: HR 2.97, 95% 
CI 1.36–6.47, p = 0.006). 
Ladoire et al. (21) evaluated the prognostic 
impact of BMI, SFA, and VFA in French 
patients with mRCC using similar methods 
as Steffens et al. The median was used to 
dichotomize SFA and VFA values into high 
versus low. High VFA was associated with 
significantly shorter time to progression and 
OS (HR 6.26, 95% CI 2.29–17.08, p < 0.001) 
in patients treated with antiangiogenic 
drugs (n = 64) but not in patients treated 
with cytokines (n = 49), on multivariate 
analysis, including MSKCC group. An obese 
BMI (> 30 kg/m2) and high SFA were not 
prognostic. Ladoire et al. suggested that 
high VFA was a predictive factor since it was 
associated with worse outcomes for patients 
treated with antiangiogenic therapy but not 
cytokines. These results differ from the 
larger IMDC dataset, in which overweight or 
obese patients (BMI ≥ 25 kg/m2) had a 
significantly longer median OS compared 
with underweight or normal patients (17). 
Gu et al. (22) retrospectively assessed BMI, 
BSA, visceral adipose tissue (VAT) index, 
subcutaneous adipose tissue (SAT), and 
SMD in mRCC patients treated with VEGF 
and mTOR therapies (n = 124). SAT and VAT 
were measured with CT at the level of the 
third lumbar vertebra and calculated with 
ImageJ software. Based on Cox regression 
modeling adjusting for age, sex, and IMDC 
criteria, both VAT and SAT indices were 
significantly associated with prolonged OS 
(VAT: HR 0.981; 95% CI 0.969–0.993, p = 
0.002; SAT: HR 0.987, 95% CI: 0.974–1.000, 
p = 0.048). However, no significant 
association was found between OS and BMI 
(p = 0.121), nor BSA (p = 0.335). Sarcopenia, 
or a depletion of skeletal muscle, can occur 
independent of adiposity. SMD had no 
significant association with OS (HR 1.000, 
95% CI 0.986–1.013, p = 0.950). 
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Table 3. Influence of volumetric assessments of body composition on clinical outcomes in 
RCC 
Study Body 
composition 
cutpoint 
Impact of body composition on outcomes 
Elevated 
body mass 
index (BMI) 
Elevated 
superficial 
fat area 
(SFA) 
Elevated 
visceral fat 
area (VAT) 
Sarcopenia 
or skeletal 
muscle 
density 
(SMD) 
Steffens et al. 
116 European 
patients (20). 
VFA and SFA 
were 
computed with 
ImageJ 
software at the 
level of the 
umbilicus 
BMI ≥ 30 
kg/m2, BSA 
above the 
European 
average > 
1.74 for 
women and 
BSA > 1.98 
for men. SFA 
or VFA above 
the median of 
the patient 
cohort 
Not 
prognostic 
High SFA, 
improved 
OS. HR 3.41 
(95% CI 
1.61–7.25,  
p = 0.001) 
High VFA, 
improved 
OS. HR 2.97 
(95% CI 
1.36–6.47,  
p = 0.006) 
N/A 
Ladoire et al. 
64 European 
patients (21). 
Baseline VFA 
and SFA were 
calculated 
with CT at the 
level of the 
umbilicus and 
calculated 
with ImageJ 
software 
BMI > 30 
kg/m2, SFA > 
median, VFA 
> median 
Not 
prognostic 
High SFA 
not 
prognostic 
High VFA 
associated 
with shorter 
OS in 
patients 
treated with 
VEGF 
inhibitors. 
HR 6.26 
(95% CI 
2.29–17.08, 
p < 0.001) 
N/A 
Gu et al. 124 
Chinese 
patients (22). 
SAT and VAT 
measured with 
CT at L3, and 
calculated 
with ImageJ 
software 
High VAT 
33.3 cm2/m2 
Not 
prognostic 
SAT 
associated 
with 
improved 
OS.  
HR 0.987 
(95% CI 
0.974–
1.000,  
p = 0.048) 
High VAT 
associated 
with 
improved 
OS.  
HR 0.981 
(95% CI 
0.969–
0.993,  
p = 0.002) 
Not 
prognostic 
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Table 3. (Continued) 
Study Body 
composition 
cutpoint 
Impact of body composition on outcomes 
Elevated 
body mass 
index (BMI) 
Elevated 
superficial 
fat area 
(SFA) 
Elevated 
visceral fat 
area (VAT) 
Sarcopenia 
or skeletal 
muscle 
density 
(SMD) 
Studies Focused on Sarcopenia 
Antoun et al. 
149 European 
and Canadian 
patients (23). 
Skeletal mass 
density 
assessed by 
CT 
SliceOMatic 
software at L3 
Sarcopenia: 
below the 
median for 
patients of 
the same sex 
within the 
study 
population 
Not 
prognostic 
SAT not 
prognostic 
VAT not 
prognostic 
Shorter OS 
(1/2) in 
patients of low 
SMD 
compared 
with high 
SMD (14 vs 
29 months,  
p = 0.001). 
Low SMD OS. 
HR 1.9 (95% 
CI 1.3–2.9) 
Antoun et al. 
55 European 
and Canadian 
patients 
treated with 
sorafenib (24). 
CT: volumetric 
assessment at 
the L3 with 
SliceOMatic 
software 
Sarcopenia: 
more than 
two standard 
deviations 
below 
average on 
volumetric 
assessment 
at L3 
Mean BMI of 
patients with 
DLT 
significantly 
lower than 
patients who 
tolerated full 
dose (23.1 vs 
26.0 kg/m2, 
p < 0.03) 
N/A N/A Males with 
sarcopenia 
more likely to 
experience 
DLT 
compared 
with 
nonsarcopenic 
(37% vs 5%,  
p < 0.04) 
McCabe et al. 
112 European 
patients (26). 
Sarcopenia 
was assessed 
using 
Appendicular 
Skeletal 
Muscle Index 
(ASMI), 
measuring at 
the L3 
landmark on 
CT 
Sarcopenia 
defined as 
ASMI <7.26 
kg/m2 for 
males and 
<5.45 kg/m2 
for females 
N/A N/A N/A Sarcopenic 
patients more 
likely to 
experience 
severe 
treatment-
related 
toxicity 
compared 
with 
nonsarcopenic 
(Pearson  
chi-square 
value 12.82,  
p = 0.001) 
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Table 3. (Continued) 
Study Body 
composition 
cutpoint 
Impact of body composition on outcomes 
Elevated 
body mass 
index (BMI) 
Elevated 
superficial 
fat area 
(SFA) 
Elevated 
visceral fat 
area (VAT) 
Sarcopenia or 
skeletal 
muscle 
density (SMD) 
Huillard et al. 
61 European 
patients 
receiving 
Sunitinib 
(27). 
Sarcopenia 
was assessed 
using L3 
landmark on 
CT, using 
software 
ImageJ 
software 
v1.42q 
Sarcopenia 
defined using 
the L3 
landmark on 
CT, with sex-
specific cutoff 
values of 
55.4 cm2/m2 
for males and 
38.9 cm2/m2 
for females 
Not 
prognostic 
N/A N/A Sarcopenics 
with BMI < 25 
more likely to 
experience DLT 
compared with 
nonsarcopenics 
with BMI > 25 
(50% vs 19.5%, 
p = 0.01) 
Cushen et al. 
55 European 
patients 
receiving 
sunitinib 
(28). Skeletal 
muscle mass 
and 
sarcopenia 
assessed 
using Osiris 
image 
software and 
measured 
with CT 
images that 
extended 
from L3 
Sarcopenia 
cutoffs 55.4 
cm2/m2 for 
males and 
38.9 cm2/m2 
for females 
Not 
prognostic 
N/A N/A Patients with 
SMM < 25th 
percentile 
experienced 
more DLT 
compared with 
those with 
SMM > 75th 
percentile  
(92% vs 57%,  
p = 0.05). 
Sarcopenia was 
not predictive 
for early DLTs 
L3: the level of the third lumbar vertebra; BMI: body mass index; BSA: body surface area; 
CI: confidence interval; DLT: dose-limiting toxicity; HR: hazard ratio; N/A: not available; OS: 
overall survival; RCC: renal cell cancer; SAT: subcutaneous adiposity tissue; SFA: 
superficial fat area; SMD: skeletal muscle density; VAT: visceral adiposity tissue. 
Antoun et al. (23) evaluated the impact of 
CT assessed body composition in a subset 
of patients from mRCC trials treated with 
sorafenib, sunitinib, everolimus, and 
placebo. When adjusted for the IMDC model 
score, mRCC patients with high SMD had 
significantly longer OS (HR 1.85; p = 0.02) 
and PFS (HR 1.81; p = 0.02), in contrast to 
patients with low SMD. Antoun et al. 
incorporated SMD into the IMDC model 
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score and created a new model. Median OS 
for patients with a favorable-risk IMDC 
model score and high SMD was 35 months 
(95% CI 24–43 months); 22 months (95% 
CI 14–27 months) for patients with an 
intermediate-risk IMDC model score and 
high SMD as well as a favorable-risk IMDC 
model score and low SMD; and 8 months 
(95% CI 6–12 months) for patients with an 
intermediate-risk IMDC model score and 
low SMD. This model has not been 
externally validated. No relationship was 
found between BMI and outcomes. SAT 
and VAT were not prognostic. 
The impact of sarcopenia on adverse 
events from targeted therapy 
Sarcopenia was evaluated in a subset of 
mRCC patients from the TARGET trial 
(sorafenib vs placebo after progression on 
standard therapy) (24). Sarcopenia was 
present in 72% of patients with a BMI < 25 
and 34% of obese patients. Treatment with 
sorafenib was associated with a significant 
decrease in skeletal muscle in comparison 
with placebo (8.0% loss, p < 0.01). Preclinical 
models suggest that the skeletal muscle loss 
associated with sorafenib may be mediated 
by downstream effects of mTOR inhibition 
(25). Frequency of sorafenib-induced dose-
limiting toxicities was highest in sarcopenic 
patients whose BMI < 25 kg/m2, and lowest 
in nonsarcopenic patients who were 
overweight or obese (p = 0.03) (24). These 
results suggest that sarcopenia in mRCC is a 
predictor of sorafenib-induced toxicity. Since 
sorafenib promotes muscle loss severe 
adverse events may be more frequent in 
sarcopenic patients. A future area of 
research would be to individualize the dose 
of a targeted therapy based on a patient’s 
skeletal muscle mass, in order to decrease 
dose-limiting toxicities and optimize clinical 
outcomes (23). 
A similar interaction between sarcopenia 
and toxicity was observed in a retrospective 
analysis of 112 mRCC patients treated with 
mTOR inhibitors, immunotherapy, VEGF 
inhibitors, Tyrosine Kinase Inhibitors (TKIs), 
and best supportive care (26). The 
prevalence of sarcopenia was 20.5% at 
baseline and increased to 38.4% at the end 
of the evaluation. Sarcopenia was 
independently associated with increased 
frequency of severe (common toxicity 
criteria grade > 2) treatment toxicity 
(Pearson chi-square value 12.82; p = 
0.001). 
Huillard et al. (27) explored the association 
between sarcopenia and toxicities in 61 
mRCC patients treated with sunitinib. 
Sarcopenia was present in 32 patients 
(52.5%), and 20 sarcopenic patients 
(32.8%) also had a BMI < 25 kg/m2. 
Patients with sarcopenia and BMI<25 
kg/m2 experienced significantly more dose-
limiting toxicities (DLTs) (OR = 4.1, 95% CI 
1.3–13.3, p = 0.01). During the first cycle, 
they also experienced more grade 3 
toxicities (p = 0.04), as well as more 
cumulative grade 2 or 3 toxicities (p = 
0.008). Sunitinib was permanently 
discontinued during the first cycle in 30% 
of sarcopenic patients, as compared with 
2.4% of the remaining patients (p = 0.01). 
On multivariate analysis, the combination 
of sarcopenia and BMI<25 kg/m2 was the 
only independent predictor of early DLTs (p 
= 0.04). However, the presence of 
sarcopenia had no significant impact on 
OS (p = 0.75) and PFS (p = 0.071). 
Cushen et al. (28) investigated the impact 
of fat-free mass and skeletal muscle mass 
(SMM; metabolic tissues such as the liver 
and kidney, intracellular and extracellular 
water, and bone) on DLTs in mRCC 
patients treated with sunitinib. Sarcopenia 
was present in 33% of the patients (18/55). 
DLTs were inversely associated with SMM; 
92% of the patients with SMM < 25th 
percentile experienced DLTs, in contrast to 
57% of those patients with SMM > 75th 
percentile (p = 0.05). Patients with low fat-
free mass (n = 4) experienced significantly 
more DLTs than those with high fat-free 
mass (n = 2, p = 0.002), but it is unclear 
what cutoff was used to determine the 
differentiation between these two groups. 
Discussion 
The IMDC database has the largest series 
of patients evaluating the impact of BMI on 
outcomes in mRCC patients treated with 
targeted therapy. OS was significantly 
improved in overweight patients (BMI ≥ 25 
kg/m2), and this observation was 
externally validated in patients who 
participated in Pfizer trials (17, 18). FASN 
gene is an emerging oncogene in mRCC, 
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and high BMI may be a surrogate for low 
FASN levels. If this finding is externally 
validated prospectively, future studies 
should optimize the FASN assay and 
determine whether inhibition of this 
pathway has the potential to improve 
outcomes for mRCC. 
CT may provide a more refined description of 
body composition than relatively crude 
measurements such as BMI. The impact of 
adipose tissue on mRCC outcomes is 
unclear. High VFA and SFA were associated 
with improved OS in studies performed by 
Steffens et al. (20) and Gu et al. (22). 
Conversely, increased VFA was associated 
with worse outcomes were in Ladoire’s cohort 
(21). Antoun et al. (23) found no association 
between VFA or SFA and outcomes. 
Sarcopenia was associated with worse 
outcomes by Antoun et al. (23), but not in 
the cohort evaluated by Gu et al. (22). These 
four cohorts did not observe a significant 
association of BMI with outcomes, but were 
all smaller than the IMDC cohort (17). These 
investigators used different combinations of 
imaging software programs and anatomical 
landmarks. Further refinement of this 
technology is required, and the cutpoints for 
sarcopenia, VFA, and SFA require further 
validation in a larger cohort of patients. 
These studies also focused on baseline 
measurements of BMI, and SFA and VFA 
(17, 18, 20–23). Further studies evaluating 
the paradox of obesity being a risk factor as 
wells a prognostic marker of response to 
targeted therapy are needed. 
Toxicity from targeted therapy appears to be 
independent of BMI (17, 18). Retrospective 
series evaluating sarcopenia consistently 
demonstrate a relationship between 
sarcopenia and increased toxicity from 
targeted agents (24, 26–28). These studies 
were small, and the ideal method for 
evaluating sarcopenia as well as the optimum 
cutoff point has yet to be established. 
What is the impact of sarcopenia on mRCC 
patients who are treated with targeted 
therapy? Sarcopenia is consistently 
associated with increased toxicity to 
inhibitors of angiogenesis and mTOR. A 
structured exercise program and dietary 
intervention may strengthen patients with 
mRCC and improve response to targeted 
therapy. Prospective studies evaluating the 
impact of diet and exercise on targeted 
therapy tolerance, quality of life, and body 
composition are warranted. 
Future longitudinal studies should 
evaluate the prognostic impact of 
sarcopenia, VAT, SFA, BMI, and BSA in 
mRCC patients treated with targeted 
therapy. This would require controlling for 
other prognostic variables in a very large 
patient cohort to fully address this issue. 
This may facilitate the development of more 
refined prognostic models of mRCC treated 
with targeted therapy. 
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